Literature DB >> 8851582

In vitro antibacterial activity of omeprazole and its selectivity for Helicobacter spp. are dependent on incubation conditions.

J E Sjöström1, J Fryklund, T Kühler, H Larsson.   

Abstract

Factors affecting the in vitro antibacterial activity of omeprazole were studied. Our data show that 3H-labeled omeprazole covalently bound to Helicobacter pylori and to other gram-negative and gram-positive bacteria. The compound was found to bind to a broad range of proteins in H. pylori, and at pH 5, binding was enhanced 15-fold compared with binding at pH 7. The bactericidal activity correlated to the degree of binding, and at pH 5, a pH at which omeprazole readily converts to the active sulfenamide form, beta-mercaptoethanol, a known scavenger of sulfenamide, and fetal calf serum, to which noncovalent protein binding of omeprazole is known to occur, reduced the level of binding and almost entirely abolished the bactericidal activity. At pH 7 the killing activities of omeprazole and structural analogs (e.g., proton pump inhibitors) were dependent on the time-dependent conversion (half-life) to the corresponding sulfenamide. The bactericidal activity exerted by the sulfenamide form at pH 5 was not specific for the genus Helicobacter. However, in brucella broth at pH 7 with 10% fetal calf serum, only Helicobacter spp. were susceptible to omeprazole, with MBCs in the range of 32 to 64 micrograms/ml, and MBCs for more stable proton pump inhibitors were higher. Wild-type H. pylori and its isogenic urease-deficient mutant were equally susceptible to omeprazole. Thus, the urease is not a lethal target for omeprazole action in H. pylori. In conclusion, the antibacterial activities of omeprazole and analogs are dependent on pH and the composition of the medium used. Thus, at a low pH in buffer, these compounds have a nonselective action, whereas in broth at neutral pH, the mechanism of action is selective for Helicobacter spp.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8851582      PMCID: PMC163169     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  19 in total

1.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

Review 2.  Diurnal profiles of gastrointestinal regulatory peptides.

Authors:  R Jorde; P G Burhol
Journal:  Scand J Gastroenterol       Date:  1985-01       Impact factor: 2.423

Review 3.  In vitro susceptibility testing of Helicobacter pylori to antimicrobial agents: basis for treatment or microbiologists' obsession?

Authors:  Y Glupczynski
Journal:  Zentralbl Bakteriol       Date:  1993-09

4.  Identification and characterization of an ATPase system of Helicobacter pylori and the effect of proton pump inhibitors.

Authors:  F Mauch; G Bode; P Malfertheiner
Journal:  Am J Gastroenterol       Date:  1993-10       Impact factor: 10.864

5.  Substituted benzimidazoles inhibit gastric acid secretion by blocking (H+ + K+)ATPase.

Authors:  E Fellenius; T Berglindh; G Sachs; L Olbe; B Elander; S E Sjöstrand; B Wallmark
Journal:  Nature       Date:  1981-03-12       Impact factor: 49.962

6.  Structure-activity relationship of omeprazole and analogues as Helicobacter pylori urease inhibitors.

Authors:  T C Kühler; J Fryklund; N A Bergman; J Weilitz; A Lee; H Larsson
Journal:  J Med Chem       Date:  1995-12-08       Impact factor: 7.446

Review 7.  Hp and pH: implications for the eradication of Helicobacter pylori.

Authors:  R H Hunt
Journal:  Scand J Gastroenterol Suppl       Date:  1993

8.  Hydrogen ion concentration in the mucus layer on top of acid-stimulated and -inhibited rat gastric mucosa.

Authors:  C Schade; G Flemström; L Holm
Journal:  Gastroenterology       Date:  1994-07       Impact factor: 22.682

9.  Specific labelling of gastric H+,K+-ATPase by omeprazole.

Authors:  J Fryklund; K Gedda; B Wallmark
Journal:  Biochem Pharmacol       Date:  1988-07-01       Impact factor: 5.858

10.  Partial characterization and effect of omeprazole on ATPase activity in Helicobacter pylori by using permeabilized cells.

Authors:  W A Belli; J Fryklund
Journal:  Antimicrob Agents Chemother       Date:  1995-08       Impact factor: 5.191

View more
  10 in total

1.  Basis for the selective antibacterial activity in vitro of proton pump inhibitors against Helicobacter spp.

Authors:  J E Sjøstrøm; T Kühler; H Larsson
Journal:  Antimicrob Agents Chemother       Date:  1997-08       Impact factor: 5.191

2.  Growth and survival of Helicobacter pylori in defined medium and susceptibility to Brij 78.

Authors:  N Albertson; I Wenngren; J E Sjöström
Journal:  J Clin Microbiol       Date:  1998-05       Impact factor: 5.948

3.  Antileishmanial activity of the antiulcer agent omeprazole.

Authors:  Suping Jiang; Juliana Meadows; Steven A Anderson; Antony J Mukkada
Journal:  Antimicrob Agents Chemother       Date:  2002-08       Impact factor: 5.191

4.  Effect of glycine on Helicobacter pylori in vitro.

Authors:  Masaaki Minami; Takafumi Ando; Shin-Nosuke Hashikawa; Keizo Torii; Tadao Hasegawa; Dawn A Israel; Kenji Ina; Kazuo Kusugami; Hidemi Goto; Michio Ohta
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

Review 5.  Marine polysaccharides in pharmaceutical applications: an overview.

Authors:  Paola Laurienzo
Journal:  Mar Drugs       Date:  2010-09-02       Impact factor: 5.118

6.  Omeprazole may exert both a bacteriostatic and a bacteriocidal effect on the growth of Helicobacter pylori (NCTC 11637) in vitro by inhibiting bacterial urease activity.

Authors:  F Mirshahi; G Fowler; A Patel; G Shaw
Journal:  J Clin Pathol       Date:  1998-03       Impact factor: 3.411

Review 7.  Proton pump inhibitors. Pharmacology and rationale for use in gastrointestinal disorders.

Authors:  P Richardson; C J Hawkey; W A Stack
Journal:  Drugs       Date:  1998-09       Impact factor: 9.546

8.  Binding of omeprazole to protein targets identified by monoclonal antibodies.

Authors:  Naw May Pearl Cartee; Michael M Wang
Journal:  PLoS One       Date:  2020-09-18       Impact factor: 3.240

Review 9.  Are antibacterial effects of non-antibiotic drugs random or purposeful because of a common evolutionary origin of bacterial and mammalian targets?

Authors:  Axel Dalhoff
Journal:  Infection       Date:  2020-12-15       Impact factor: 3.553

10.  The Anti-virulence Efficacy of 4-(1,3-Dimethyl-2,3-Dihydro-1H-Benzimidazol-2-yl)Phenol Against Methicillin-Resistant Staphylococcus aureus.

Authors:  Nagendran Tharmalingam; Rajamohammed Khader; Beth Burgwyn Fuchs; Eleftherios Mylonakis
Journal:  Front Microbiol       Date:  2019-07-17       Impact factor: 5.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.